About this course

The course highlights the current trends in the treatment of melanoma, focusing on personalised medicine and the evidence base for combination treatment with BRAFi + MEK inhibitor in melanoma and existing clinical trials. The course also discusses adverse event management and introduces the clinical trials that examined adjuvant therapy with checkpoint inhibitors or targeted therapy in melanoma patients with high risk of recurrence.

Sponsored by